Sign up
OPK

Opko Health Inc (NASDAQ: OPK)

Healthcare · Diagnostics & Research

$1.69+0.07 (+4.32%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. OPK rose 4.32% in the Nov 18 session to $1.69, which is 4.5% below its 52-week high of $1.77. Short interest is 10.27% of float with a 0.41% borrow fee. Three active firms cover the stock as of Nov 19, 2026; two active firms with targets average $2.75 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 53.4 (overbought above 70, oversold below 30)

Trend—

—

Short interest10.3% of float

FINRA settlement Oct 30, 2026

OPK price chart

Price $1.69 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$1.61Nov 18, 2026 session
Previous close
$1.62Nov 17, 2026 close
Day range
$1.61 – $1.71Nov 18, 2026 session
52-week range
$1.10 – $1.77Through Nov 18, 2026
Volume
3.06MNov 18, 2026 session
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$1.24B
P/E (TTM)negative earnings —
Forward P/E—
EPS (TTM)stale vendor snapshot —
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)1.50

Price history

OPK · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18

Insufficient data · Tide session Nov 18, 2026

Tide69High Tide—
Squeeze41Watch—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

0Strong Buy
2Buy
1Neutral
0Sell
0Strong Sell

Based on 3 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$1.50
Average$2.75
High$4.00

As of Nov 19, 2026 across 2 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.06−$0.07—
Q2 2026—−$0.01—
Q1 2026—−$0.07—
Annual 2025—−$0.30—
Q3 2025—$0.03—
Q2 2025—−$0.19—
Q3 2024−$0.09$0.03—
Q1 2023−$0.08−$0.02—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All OPK news →

Company profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to

CEO
Dr. Phillip Frost M.D., Ph.D.
Headquarters
Miami, FL, United States
Employees
2,275
IPO date
Nov 2, 1995
Sector
Healthcare
Industry
Diagnostics & Research
Website
opko.com

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.